The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
 
Monika Graeser
Consulting or Advisory Role - AstraZeneca Canada
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo
 
Oleg Gluz
Honoraria - AstraZeneca; Celgene; Genomic Health/Exact Sciences; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - Celgene; Genomic Health/Exact Sciences; Gilead Sciences; Lilly; Molecular Health; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Roche
 
Christine zu Eulenburg
Honoraria - Lilly
Consulting or Advisory Role - HMNC Brain Health
 
Sherko Kuemmel
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Hologic; Lilly; MSD Oncology; Novartis; Pfizer; PINK; Roche/Genentech; Seagen; Sonoscape; Stemline Therapeutics; Stryker
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Matthias Christgen
No Relationships to Disclose
 
Rachel Wuerstlein
Honoraria - Agendia; Amgen; Apogheva; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene/Jazz; ClinSol; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Medstrom Medical; MSD; Mundipharma; Mylan; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman; Pfizer; Pierre Fabre; PINK; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Sidekick Health; Stemline Therapeutics; Tesaro; Teva; Veracyte; Viatris; Wiley
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
Speakers' Bureau - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seattle Genetics/Astellas; Tesaro; Teva
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Lilly; MSD; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; Riemser; Roche; Sandoz/Hexal; Seagen; Tesaro; Teva
 
Hans Kreipe
Honoraria - AstraZeneca; Exact Sciences; Lilly; Roche
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Lilly; Roche
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Marc Thill
Honoraria - Agendia; Amgen; Art Tempi; AstraZeneca; Eisai; Exact Sciences; Gedeon Richter; Gilead Sciences; GlaxoSmithKline; Hexal; I-Med-Institute; Jörg Eickeler; Laborarztpraxis Walther et al.; Lilly; Medscape; MSD; Novartis; Onkowissen; Pfizer; pfm medical; Roche; Seagen; Stemline Therapeutics; StreamedUp; Sysmex; Viatris; Vifor Pharma; ZP Therapeutics
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Aurikamed; Becton Dickinson; ClearCut Medical; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; Merck; MSD; Neodynamics; Novartis; Onkowissen; Pfizer; pfm Medical; Pierre Fabre; Roche; Seagen; Sirius Medical; Sysmex
Research Funding - AstraZeneca (Inst); Biom’Up (Inst); CairnSurgical (Inst); ClearCut Medical (Inst); Endomag (Inst); Exact Sciences (Inst); Neodynamics (Inst); Novartis (Inst); pfm medical (Inst); Roche (Inst); RTI Health Solutions (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Gilead Sciences; Hexal; Lilly; Neodynamics; Novartis; Pfizer; Pierre Fabre; Roche; Sirius Medical
 
Michael Braun
Honoraria - AstraZeneca; Daiichi Sankyo; Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; Novartis; Pfizer; Puma Biotechnology; Roche; Sirius Medical
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Medac; Novartis; Roche
 
Claudia Schumacher
No Relationships to Disclose
 
Joke Tio
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Gilead Sciences; Lilly; Molecular Health; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai Germany; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Gilead Sciences; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Pfizer
 
Johannes Schumacher
Employment - Palleos
 
Andreas Hartkopf
Honoraria - Agendia; Amgen; AstraZeneca; Daiichi Sankyo; Genomic Health; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
 
Chrisitan Schem
Honoraria - AstraZeneca; Exact Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Speakers' Bureau - AstraZeneca; Novartis; Roche
Research Funding - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche
 
Kerstin Luedtke-Heckenkamp
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Menarini Group; MSD; Novartis; Pfizer; Roche; Seagen
 
Felix Hilpert
Honoraria - AstraZeneca; Clovis Oncology; MSD; Novartis; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Tesaro
 
Ronald Kates
Stock and Other Ownership Interests - West German Study Group (I)
Honoraria - AstraZeneca (I); Daiichi Sankyo (I); Gilead Sciences (I); Novartis (I); Pfizer (I); Pierre Fabre (I); Roche (I)
Consulting or Advisory Role - Daiichi Sankyo (I); Novartis (I); Pfizer (I); Roche (I); Sandoz (I); Seagen (I)
Research Funding - Lilly (I); MSD (I); Novartis (I); Pfizer (I); Roche/Genentech (I)
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic Health; Roche; Seagen
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Roche/Genentech; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)